The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

OMB APPROVAL OMB Number: Estimated average burden hours per response:

Notice of Exempt Offering of Securities

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001492422			X Corporation
Name of Issuer			Limited Partnership
Apellis Pharmaceuticals, Inc.			
Jurisdiction of Incorporation/	Organization		Limited Liability Company
DELAWARE			General Partnership
Year of Incorporation/Organiz	zation		Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (S	Specify Vear)		
	specify real)		
Yet to Be Formed			
2. Principal Place of Busine	ess and Contact Information		
Name of Issuer			
Apellis Pharmaceuticals, Inc.			
Street Address 1		Street Address 2	
6400 WESTWIND WAY		SUITE A	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
CRESTWOOD	KENTUCKY	40014	502-241-4114
3. Related Persons			
Last Name	First Name		Middle Name
François	Cedric		
Street Address 1	Street Address 2		
6400 Westwind Way	Suite A		
City	State/Province/Co	untry	ZIP/PostalCode
Crestwood	KENTUCKY		40014
Relationship: X Executive C	Officer X Director Promoter		
Clarification of Response (if N	Necessary):		
Last Name	First Name		Middle Name
Deschatelets	Pascal		
Street Address 1	Street Address 2		
6400 Westwind Way	Suite A		
City	State/Province/Co	untry	ZIP/PostalCode
Crestwood	KENTUCKY		40014
Relationship: X Executive C	Officer Director Promoter		
Clarification of Response (if N	lecessary):		
Last Name	First Name		Middle Name
Dunlop	A.		Sinclair
Street Address 1	Street Address 2		
7910 Woodmont Avenue	Suite 1210		

City State/Province/Country		ZIP/PostalCode		
Bethesda	MARYLAND	20814		
Relationship: Executive Offi	icer X Director Promoter			
Clarification of Response (if Neo	cessary):			
Last Name	First Name	Middle Name		
Machiels	Alec			
Street Address 1	Street Address 2			
6400 Westwind Way	Suite A			
City	State/Province/Country	ZIP/PostalCode		
Crestwood	KENTUCKY	40014		
Relationship: Executive Offi	icer X Director Promoter			
Clarification of Response (if Neo	cessary):			
Last Name	First Name	Middle Name		
Chan	Gerald			
Street Address 1	Street Address 2			
1188 Centre Street				
City	State/Province/Country	ZIP/PostalCode		
Newton	MASSACHUSETTS	02459		
Relationship: Executive Offi	icer X Director Promoter			
Clarification of Response (if Neo	cessary):			
Last Name	First Name	Middle Name		
O'Brien	Stephanie			
Street Address 1	Street Address 2			
1188 Centre Street				
City	State/Province/Country	ZIP/PostalCode		
Newton	MASSACHUSETTS	02459		
Relationship: Executive Offi	icer X Director Promoter			
Clarification of Response (if Neo	cessary):			
4. Industry Group				

Agriculture	Health Care	
Banking & Financial Services	X Biotechnology	☐ Retailing
Commercial Banking	Health Insurance	Restaurants
Insurance	Hospitals & Physicians	Technology
Investing		Computers
Investment Banking	Pharmaceuticals	Telecommunications
Pooled Investment Fund	Other Health Care	
Is the issuer registered as an investment company under	Manufacturing	Other Technology
the Investment Company	Real Estate	Travel
Act of 1940?	Commercial	Airlines & Airports
YesNo	Construction	Lodging & Conventions
Other Banking & Financial Services	REITS & Finance	Tourism & Travel Services
Business Services	Residential	Other Travel
Energy	Other Real Estate	Other
Coal Mining	Other Real Estate	Other Control
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		
5. Issuer Size		
J. IOUGOI GIEG		
Revenue Range OR	Aggregate Net Asset V	alue Range
	Aggregate Net Asset V	
Revenue Range OR		
Revenue Range OR No Revenues	No Aggregate Net A	sset Value
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000	No Aggregate Net A \$1 - \$5,000,000	o,000
Revenue Range OR No Revenues \$\begin{align*} \text{X} \\$1 - \\$1,000,000 \\ \$\\$1,000,001 - \\$5,000,000 \\ \$\\$5,000,001 - \\$25,000,000 \\ \$\\$25,000,001 -	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000	0,000 00,000
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,000 \$50,000,001 - \$100,000	0,000 00,000
Revenue Range OR No Revenues \$\begin{align*} \text{X} \\$1 - \\$1,000,000 \\ \$\\$1,000,001 - \\$5,000,000 \\ \$\\$5,000,001 - \\$25,000,000 \\ \$\\$25,000,001 -	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,00	0,000 00,000
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,000 \$50,000,001 - \$100,000 Over \$100,000,000	0,000 00,000
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,00 \$50,000,001 - \$100,0 Over \$100,000,000 Decline to Disclose Not Applicable	0,000 00,000 000,000
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,000 \$50,000,001 - \$100,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply)	0,000 00,000 000,000
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,000 \$50,000,001 - \$100,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply)	0,000 00,000 000,000
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Classical Exemption (s)	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,000 \$50,000,001 - \$100,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Investment Compa	any Act Section 3(c)
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,000 \$50,000,001 - \$100,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Investment Compa	sset Value 0,000 00,000 000,000 any Act Section 3(c) Section 3(c)(9) Section 3(c)(10)
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,00 \$50,000,001 - \$100,0 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Investment Compa	sset Value 0,000 00,000 000,000 any Act Section 3(c) Section 3(c)(9)
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 504 (b)(1)(iii) Rule 505	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,000 \$50,000,001 - \$100,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Investment Compa	sset Value 0,000 00,000 000,000 any Act Section 3(c) Section 3(c)(9) Section 3(c)(10)
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Class Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 505 X Rule 506(b)	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,00 \$50,000,001 - \$100,0 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Investment Compa Section 3(c)(1) Section 3(c)(2) Section 3(c)(3)	any Act Section 3(c) Section 3(c)(10) Section 3(c)(11)
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Class Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 505 X Rule 506(b) Rule 506(c)	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,00 \$50,000,001 - \$100,0 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Investment Compa Section 3(c)(1) Section 3(c)(2) Section 3(c)(3) Section 3(c)(4) Section 3(c)(5)	sset Value 0,000 00,000 000,000 any Act Section 3(c) Section 3(c)(9) Section 3(c)(10) Section 3(c)(11) Section 3(c)(12) Section 3(c)(13)
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Class Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 505 X Rule 506(b)	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,000 \$50,000,001 - \$100,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Investment Compa Section 3(c)(1) Section 3(c)(2) Section 3(c)(3) Section 3(c)(4) Section 3(c)(5) Section 3(c)(6)	sset Value 0,000 00,000 000,000 any Act Section 3(c) Section 3(c)(9) Section 3(c)(10) Section 3(c)(11) Section 3(c)(12)
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Class Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 505 X Rule 506(b) Rule 506(c)	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,00 \$50,000,001 - \$100,0 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Investment Compa Section 3(c)(1) Section 3(c)(2) Section 3(c)(3) Section 3(c)(4) Section 3(c)(5)	sset Value 0,000 00,000 000,000 any Act Section 3(c) Section 3(c)(9) Section 3(c)(10) Section 3(c)(11) Section 3(c)(12) Section 3(c)(13)
Revenue Range OR No Revenues X \$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Class Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 505 X Rule 506(b) Rule 506(c)	No Aggregate Net A \$1 - \$5,000,000 \$5,000,001 - \$25,000 \$25,000,001 - \$50,000 \$50,000,001 - \$100,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Investment Compa Section 3(c)(1) Section 3(c)(2) Section 3(c)(3) Section 3(c)(4) Section 3(c)(5) Section 3(c)(6)	sset Value 0,000 00,000 000,000 any Act Section 3(c) Section 3(c)(9) Section 3(c)(10) Section 3(c)(11) Section 3(c)(12) Section 3(c)(13)

New Notice Date of First Sale 2014-12-05 First Sale Yet t X Amendment	to Occur	
8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	Yes X No	
9. Type(s) of Securities Offered (select all that apply)		
 X Equity Debt Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or CRight to Acquire Security 	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combination of exchange offer? Clarification of Response (if Necessary):	ation transaction, such as a Yes X No	
11. Minimum Investment		
Minimum investment accepted from any outside investor \$10,000	USD	
12. Sales Compensation		
Recipient	Recipient CRD Number X None	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None	
Street Address 1	Street Address 2	
City	State/Province/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States All States	Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$17,732,150 USD or Indefinite		
Total Amount Sold \$17,732,150 USD		
Total Remaining to be Sold \$0 USD or Indefinite		
Clarification of Response (if Necessary):		
14. Investors		
Select if securities in the offering have been or may be sold to enter the number of such non-accredited investors who alread		
Regardless of whether securities in the offering have been or investors, enter the total number of investors who already have		1
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finders estimate and check the box next to the amount.	fees expenses, if any. If the amount of an expenditure is no	ot known, provide an
Sales Commissions \$0 USD Estimate		
Finders' Fees \$0 USD Estimate		
Clarification of Response (if Necessary):		
16. Use of Proceeds		

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the

hov	novt	to	tha	amount	

\$0 USD	Estimate
30 030	⊏Stiiiiate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Apellis Pharmaceuticals, Inc.	Cedric François	Cedric Francois	Chief Executive Officer	2015-06-09

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.